OptiNose, Inc.
(NASDAQ GS: OPTN)
Rigrodsky Law, P.A. is investigating OptiNose, Inc. (“OptiNose”) regarding possible breaches of fiduciary duties and other violations of law related to OptiNose’s agreement to be acquired by Paratek Pharmaceuticals. Under the terms of the agreement, OptiNose shareholders will receive $9.00 per share in cash plus up to $5.00 per share in contingent value rights payable in the event that certain net revenue milestones are achieved.